Most of the attention on next week's FDA panel treats it as one big up-or-down moment. It isn't. The July 23-24 meeting is tranche one of a phased review, and five more peptides are already lined up behind it.
When the FDA's Pharmacy Compounding Advisory Committee meets next Thursday and Friday, it will review seven peptides, BPC-157, KPV, TB-500 and MOTS-c on day one; Emideltide (DSIP), Semax and Epitalon on day two. The question is whether any belong on the 503A Bulk Drug Substances List, the legal precondition for a licensed pharmacy to compound them under a prescription. [1]
What's easy to miss is that seven is not the whole list. When the FDA announced the meeting in the Federal Register on April 16, it framed this as a review of substances that were moved into "Category 2" back in 2023, a holding bin for bulk substances the agency had significant concerns about and was not ready to allow in compounding. [2]
Trade coverage of the docket has described a review of roughly a dozen peptides being worked through in stages rather than all at once. [3] Reporting on the schedule indicates a second PCAC meeting is expected before the end of February 2027 to take up five more, GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate and Pegylated Mechano Growth Factor (PEG-MGF). Seven now, five later, out of the group the agency reclassified in 2023.
Two things are worth holding onto as the noise builds. First, on the science, none of this is a verdict. The FDA's own briefing materials propose not adding the seven, citing substances that are not well characterized and thin human data on safety and effectiveness for the mostly injectable uses under review. [4] Statements about these peptides have not been evaluated by the FDA, and nothing here is medical advice.
Second, on the process, a panel vote changes nothing by itself. The recommendation is advisory and non-binding; even a "yes" would still require the FDA to open formal rulemaking, with its own public comment window, before a single pharmacy could legally compound anything. That is normally a matter of many months. The public comment docket, FDA-2025-N-6895, closes July 22. [5]
Here is where we're coming from, stated plainly: Peppies is an independent, for-profit venture, and we argue for one thing, a legal, tested, regulated pathway, because a supervised prescription from a licensed pharmacy is safer than an unregulated grey market where nobody verifies what's in the vial. That is our stated position, not a neutral finding, and we'd benefit only from a future legal market. A phased review is the system doing its slow, unglamorous job, and the pace is the point. We'll publish a plain-English readout after each meeting.
Sources
- FDA, July 23-24, 2026 PCAC meeting notice
- Federal Register, PCAC notice of meeting (Apr 16, 2026)
- RAPS, FDA considers adding a dozen peptides to its bulk drug compounding list
- Foley & Lardner, FDA to consider lifting restrictions on numerous compounded peptides
- Regulations.gov, docket FDA-2025-N-6895
The moment that counts comes later. When the FDA opens the public comment window that carries legal weight, we'll tell you. Get notified →